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Radio Guided Surgery is a technique helping the surgeon in the resection of tumors: a radiolabeled 
tracer is administered to the patient before surgery and then the surgeon evaluates the completeness 
of the resection with a handheld detector sensitive to emitted radiation. Established methods rely on γ 
emitting tracers coupled with γ detecting probes. The efficacy of this technique is however hindered by 
the high penetration of γ radiation, limiting its applicability to low background conditions. To overtake 
such limitations, a novel approach to RGS has been proposed, relying on β− emitting isotopes together 
with a dedicated β probe. This technique has been proved to be effective in first ex-vivo trials. We 
discuss in this paper the possibility to extend its application cases to 68Ga, a β+ emitting isotope widely 
used today in nuclear medicine. To this aim, a retrospective study on 45 prostatic cancer patients was 
performed, analysing their 68Ga-PSMA PET images to asses if the molecule uptake is enough to apply 
this technique. Despite the expected variability both in terms of SUV (median 4.1, IQR 3.0–6.1) and TNR 
(median 9.4, IQR 5.2–14.6), the majority of cases have been found to be compatible with β-RGS with 
reasonable injected activity and probing time (5 s).
Radioguided surgery (RGS) is a technique helping the surgeon to achieve a resection of the tumor as complete 
and precise as possible. In this technique, a radiolabeled tracer, that is preferentially taken up by the tumor, is 
administered to the patient before the surgery. During the procedure itself, the surgeon is then provided with an 
handheld detector (named probe) that, being sensitive to radiation emitted by the tracer, allows to recognise areas 
of high uptake of the molecule, thus suggesting the possible presence and extension of the tumoral cells.
Established methods use nowadays a combination of a γ-emitting tracer with a γ-radiation-detecting probe1,2. 
However, since γ radiation can penetrate large amounts of tissue, any uptake of the tracer in nearby healthy tissue 
represents a non-negligible background, that often limits or eventually prevents the use of this technique.
To overcome these limits and extend the range of applicability of RGS, it was suggested3 to use pure β −emit-
ting radio-isotopes instead of γ-emitting tracers. In fact, β− radiation penetrates only few millimetres of tissue 
with essentially no γ contamination, since the bremsstrahlung contribution, that has a 0.1% emission probability 
at β-product energies, can be considered negligible4. Such a technique would allow a clearer delineation of mar-
gins of the lesioned tissue together with a substantial reduction (due to low penetration of β− particles) of the dose 
given to the medical staff. A proper detector has been developed to test the technique. This β− probe is character-
ised by high sensitivity to β particles, whilst being substantially transparent to γ  contamination. In the recent 
years, this proposed novel technique of RGS has been proved not only to be theoretically possible5,6, but also its 
actual feasibility has been demonstrated with ex-vivo tests on meningioma samples marked with 90Y-DOTATOC7.
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Despite the success of these first clinical trials, the fact that basically only somatostatin analogues can currently 
be marked with a pure β− emitter (90Y) poses a strong limitation to the possible applications of this technique. To 
this purpose, a systematic study of the detector performances with several radioisotopes (mainly focusing on 
“non pure” β− emitters) has been performed8. In this study, also 18F was considered, due to the huge amount of 
application cases the extension to such an isotope would represent. However, it turned out that at the current 
status, the β probe does not allow an efficient detection of the emitted radiation, its efficacy being limited mainly 
by the low energy endpoint of emitted β+ particles, rather than by the copious background of annihilation pho-
tons, for which the probe is essentially transparent.
In this context, 68Ga could in principle be an interesting isotope for an extention of the technique. It is in fact 
another widespread β+ emitting isotope, commonly used in many fields of oncologic applications, not only in the 
diagnosis of Neuroendocrine Tumors (NET) labelled with different peptides such as DOTA-NOC, DOTA-TOC, 
DOTA-TATE9 but also, more recently, with the advent of Ga-labelled PSMA compounds such as PSMA 11 and 
PSMA 61710. The main difference with respect to 18F is represented by the much higher energy end point for the 
β particle, that is of 1.899 MeV (to be compared to .0 633MeV of 18F and to .2 280MeV of the β− spectrum of 90Y). 
The beta energy endpoint of 68Ga is thus similar to the one of 90Y, whilst the unavoidable γ background due to 
positron annihilation holds as a substantial difference between the two cases. However, in presence of favourable 
conditions in terms of both absolute and relative to the healthy tissue uptake of the tumor, the low sensitivity of 
the probe to photons could allow to use β-RGS also with 68Ga.
All in all, the main concern with the abundant γ emission would be represented by radio-protection issues of 
the medical personnel and the patient, for which the same considerations standing for currently used γ-RGS hold. 
However, the high sensitivity of the detector to positrons allows to reduce the activity to inject to the patient, and 
thus the dose given to the personnel. On the other side, the dose to the patient would be comparable to a PET 
scan.
The aim of this study is thus to evaluate the feasibility of such a technique in a first application case involving 
68Ga besides somatostatin analogues, namely lymphoadenectomy in case of prostatic surgery with 68Ga-PSMA.
In the last few years, PSMA PET has emerged as an accurate tool to detect metastatic lymph nodes (LNs), 
especially in patients with high risk for distant involvement at presentation or in patients showing Biochemical 
Recurrence (BCR) of prostate cancer, candidates or eligible for salvage lymphadenectomy11. In both primary 
staging or in salvage surgery procedures in case of BCR the localisation of small lymph nodes may result difficult 
for surgeons, especially if the lymph nodes are located in atypical sites. The use of Radio Guided Surgery may help 
surgeons in the detection of such small metastatic lymph nodes with the aim of increasing accuracy, reducing the 
operation time and improving oncological outcome12.
The use of 68Ga-PSMA as radiopharmaceutical has the advantage to allow at the same time preoperative imag-
ing using PET and radio surgical guidance using dedicated beta probes. In this paper we have studied retrospec-
tively PET scans of patients with prostate cancer after administration of 68Ga-PSMA. Following the procedure in 
ref.5, we use the measured uptake in tumor and nearby healthy tissues to evaluate the sensitivity of a probe, 
designed for β radiation13, to the signals of interest, thus evaluating the feasibility of the application of RGS in this 
case.
Materials and Methods
Patients selection. Since the aim of this study is to evaluate the feasibility of β-RGS in patients with pros-
tatic cancer showing increased uptake for 68Ga-PSMA-11 (HBED-CC) (hereinafter called simply “68Ga-PSMA”) 
at PET/CT investigation, we selected 45 patients with a positive exam performed either for staging or restaging in 
case of relapse (1 patient was T1N0M0, 12 pts were T2N0M0, 5 were T2N1M0, 21 pts were T3N0M0, 6 were 
T3N1M0). PET/CT scans were performed at Policlinico Sant’Orsola Malpighi in Bologna following standard 
acquisition methods. We collected data for 58 different lesions, either in the prostatic gland or other lymph nodal 
localisations. All patients gave written informed consent to participate in the clinical research. The study, as part 
of a larger trial on prostate cancer imaging with PET14, has been approved by the Ethics Committee of the 
Policlinico Sant’Orsola Malpighi. Moreover, this research is compliant with applicable Italian law and with the 
Charter of Fundamental Rights of the European Union (in particular with Art. 3 and Art. 8), the Declaration of 
Helsinki, the Oviedo Bioethics Convention and the European Union Regulation N. 536/2014 of the European 
Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 
2001/20/EC.
Estimate of the PSMA Uptake. To quantify the applicability of this technique, it is necessary to know the 
SUV and TNR of PSMA in prostatic cancer.
The Standardised Uptake Value (SUV) is a parameter used to take into account the differences in administered 
activity of tracer injected to the patients, and is defined as:
μ
=
− . ∆
W
A e
SUV ,
(1)adm
t T0 693 /PET Ga
1/2
where μ is the mean value of PET activity of the considered point, Aadm is the administered activity, W mass of the 
patient, ∆tPET is the time elapsed between the administration and the PET scan, and TGa
1/2 is the 68Ga half-life.
The Tumor Non tumor Ratio (TNR) is defined as the ratio between the SUVs of the tumor and of the nearby 
healthy tissue.
Keeping in mind the application case of this study, that is the intraoperative discrimination of tumor remnants 
and/or positive lymph nodes during prostatectomy, we decided to choose as reference “healthy tissue” the area 
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around the active lesion of interest, rather than for example a healthy lymph-node with a generic localisation. It 
is in fact this one the area the surgeon must be able to eventually distinguish from the lesion in a hypothetical 
application case.
To obtain these uptakes, we examined 68Ga-PSMA PET scans of the patients in the cohort. Patients were 
injected with a 2 MBq/kg activity of 68Ga-PSMA. After a 60-min uptake period, whole-body imaging was 
performed on a bismuth germanium oxide equipped Discovery 690 PET/CT scanner (GE Healthcare) using 
a standard vertex-to-pelvis protocol. The CT acquisition protocol included low- dose CT (120 kV, automatic 
amperage, noise index 25, pitch of 1.375, and 3.75-mm slice thickness) for attenuation correction followed by a 
whole-body PET scan (3 min per bed position). The PET scans were acquired in 3-dimensional mode in a 256 
256 matrix (voxel size, 2.73 · 2.73 · 3.17 mm). Images were reconstructed using VUE Point HD (GE Healthcare) 
attenuation-weighted ordered-subsets expectation maximization (2 iterations, 16 subsets) followed by a post 
reconstruction smoothing gaussian filter (5 mm in full width at half maximum).
These PET images were retrospectively analysed with Advance GE workstation (version Advantage 4.6). In 
particular, the “3d-isocontour” tool was used to define ROIs (Regions Of Interest) throughout several slices in 
which to evaluate the mean uptake, thus forming VOIs (Volumes Of Interest). The threshold for this selecting tool 
was set to 50% of the maximum value, and the VOIs were chosen to be approximately of the order of 100mm3 in 
volume for homogeneity of comparison.
For each VOI, the average SUV ( = ∑ =SUV SUV N/iN i1 , where SUVi is referred to the individual N pixels), the 
SUV RMS (∆SUV, defined as ∑ − −= SUV SUV N( ) /( 1)iN i1
2 ) and the VOI volume (V) were measured. From this 
latter parameter, knowing the size of the voxels (Vv), the number of voxels in the VOI has been obtained by means of:
=N V
V
,
(2)v
and thus the error on the mean SUV value was calculated:
σ =
∆
.
N (3)SUV
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In some occasions, the analysis program was not able to automatically extend the ROI through several contig-
uous slices. In these cases several ROIs ( = …i n1 ) were manually created through the slices in order to achieve 
the desired target volume for the VOI, measuring for each one the average SUV (SUVi), the SUV rms (∆SUVi) and the ROI volume (Vi). Then, to obtain the average value of the SUV in the VOI, a weighted average of the single 
mean SUVs of each ROI was performed, using as weight the inverse of the error on the mean SUV of the single 
ROI (obtained as in Eq. 3), according to the following formula:
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The error on the average SUV of the VOI is then:
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Evaluation of TNR. From the average values for the SUVs in the VOIs of interest for both lesions and healthy 
tissues, Tumor Non-tumor Ratios (TNR) have been calculated. Calling SUVT and SUVH the mean SUV of the 
Tumor and of Healthy Tissue respectively, the TNR is calculated as:
= .TNR SUV
SUV (6)
T
H
The error on the TNR is obtained combining the errors on both SUVs (σSUVT and σSUVH), according to:
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The β Probe. A crucial element in the development of the proposed RGS method is the design of the detector 
to be used during the RGS procedure. As described in previous studies5,6, we developed a β probe, which exploits 
the low penetration power of β radiation by reducing the size of the lateral shielding, with the result of a light and 
handy tool, with respect to commercial γ probes. The active area of the detector is made of p-terphenyl, that is an 
organic scintillator characterised by low density and high light yield, which makes it an ideal choice to have good 
sensitivity to β particles, while being substantially transparent to photons15.
In particular, the actual probe prototype, which has been tested on β− radiation in a clinical trial with menin-
gioma ex-vivo samples7, is composed by a sensitive cylinder of p-terphenyl with a radius of 2.55 mm and a 3-mm 
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depth. To maximise the accuracy on the direction of the incoming radiation, the sensitive region is screened by 
3 mm of polyvinylchloride. The scintillation light is read by a Silicon Photo Multiplier sensor (SiPM, SenSL series 
C, mod. 10035), controlled and read out by means of the ArduSiPM electronics16.
It has to be noted that an open surgery approach is not necessarily an optimal use case for this technique, 
and indeed the final goal is to develop a detector suited for laparoscopic, eventually robotic, surgery. The design 
of the “robotic probe” is in fact already ongoing, using the same detection principle than the actual probe (scin-
tillating crystal + SiPM), but encapsulated in a small, “drop in” device to be handled by laparoscopic or robotic 
instruments.
Calculation of expected rates. In order to quantify the performances of the probe in the real application 
scenario, a benchmark surgical configuration was reproduced within a Monte Carlo (MC) simulation with the 
FLUKA program17. Two simulations have been developed. The first one reproduces the probe exposition to a 
small (∼ .0 1mL) tumoral remnant encapsulated in healthy tissue; the second one has been developed to calculate 
the background contribution of γs from the whole patient body. In the scintillator, 28000 optical photons per 
MeV of deposited energy15 are produced and tracked. To increase the simulation precision, the δ rays production 
threshold and the electron transport threshold have been set to 10 keV in the scintillator and in the materials in 
contact with it. Moreover, in these materials the electrons step size has been limited to make them loose no more 
than 1% of their energy per each step. The event is considered detected if a number of optical photons greater than 
a threshold crosses the boundary with the SiPM. Such a threshold, as the other parameters of the optical photons 
simulation, has been set using data from a dedicated measurement campaign. More details on the MC simulation 
and its optimisation can be found in8.
All in all, SUV and TNR retrieved from the retrospective study can be used to simulate the expected activity 
in the considered lesion during a possible RGS procedure. The MC code allows thus to obtain the rates, in counts 
per second (cps), we expect to count on the tumor (RT) and on the nearby healthy tissue (RH).
Obviously, such a prediction takes as an input the amount of activity injected to the patient before surgery and 
the time elapsed between the injection and the procedure. These parameters are in fact necessary to foresee the 
specific activity in the areas of interest at the time of RGS. In this study we assumed that an activity of 3MBq/kg 
of 68Ga-PSMA could be administered to the patient, thus using as a reference (for a 70kg patient) a total activity 
of 210MBq. The difference in the activity to be administered in case of RGS, with respect to the one of the PET 
scans used for the retrospective study earlier described, can be taken into account by proper normalisation, 
assuming a linear behaviour of the expected uptakes.
The choice of the time between the injection and the procedure is instead quite complex. On one hand, in fact, 
there are some technical constraints regarding the need to inject the patient, to do the pre-operative PET scan 
(needed to assess the actual uptake for PSMA) and to safely transport the patient from Nuclear Medicine to the 
Operating Room. On the other hand, however, the half-life of 68Ga is of 68min, thus implying that every hour 
elapsed a factor ∼2 of activity is lost. Therefore, in this study we assumed that the procedure is performed 
2h30min (150min) after the injection of the radiopharmaceutical.
From the estimated RT and RH it is possible to calculate the minimal probing time (tprobe) the probe needs to 
be over the target to be able to discriminate with sufficient accuracy tumor from healthy tissue.
To this aim, we applied in this study the same approach applied and described in ref.3, that relies on the esti-
mation of the rate of false positive (FP) and false negative (FN) signals. For a given value of the probe acquisition 
time (tprobe), the number of signal counts from the tumour and the background is distributed according to a 
Poisson distribution with mean μ = ×R tT T probe and μ = ×R tH H probe, respectively. Given the minimum num-
ber of signal counts (th) needed to flag a positive identification, FP is computed as the fraction of times the back-
ground would yield a positive signal:
∑= − μ
=
−
FP P N1 ( ),
(8)N
th
0
1
H
where μP N( ) indicates the Poisson probability to have N if the mean is μ. Similarly, FN is the fraction of times a 
tumour residual would not yield a signal:
∑= .μ
=
−
FN P N( )
(9)N
th
0
1
T
To determine the minimum probing time, FN and FP are computed in a grid of tprobe and th and the smallest 
value of tprobe for which <FN 5% and ≈FP 1% is determined.
ROC Analysis. By means of the procedure described in the previous section the optimal probing time for 
each lesion has been estimated. However, in the real application case, and thus during the RGS procedure, the 
time the surgeon will spend on each analysed spot is almost constant, and can not depend on the unknown actual 
activity of the lesion. First ex-vivo tests suggest that, regardless of the uptake of the sample, it is natural to spend 
on it at least ≈3 before being confident enough to discriminate if it is healthy or not.
Therefore, we performed a sensitivity analysis to evaluate the discriminating power of our technique, assum-
ing a fixed probing time of =t 3sprobe , and varying the threshold (th) in terms of total number of counts in this 
time interval. For each threshold value, “sensitivity” and “specificity” were calculated and plotted in a ROC curve, 
the area of which can be used as evaluation of the discriminating power of the proposed technique.
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Results
Uptake and TNRs. The analysis procedure described above was then applied to all the 58 lesions to obtain 
the respective SUVs and TNRs. Median SUV was 4.1 (InterQuartile Range 3.0–6.1), while median TNR was 9.4 
(IQR 5.2–14.6).
In Fig. 1 SUVs and TNRs are shown in histograms, keeping the distinction between local lesions in the pros-
tatic situs and lymph nodes, while Fig. 2 shows the scatter plot of SUV versus TNR.
Figure 1. Distribution of SUVs (top) and TNRs (bottom) for all the 58 lesions. The blue (continue) line 
represents lymph nodes, while the red (dotted) line represents local lesions.
Figure 2. Scatter plot showing SUV as a function of TNR for all the 58 lesions, dividing between local lesions 
and lymph nodes. Errors shown in the bars are obtained as described in the text.
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Sensitivity Analysis. Figure 3 (top) shows the ROC curve, obtained as described previously in the text, for 
lymph node 1 lesion. Furthermore, Fig. 3 (bottom) shows the distribution of the Area Under Curve for all the 
considered 58 lesions.
Expected Performances of RGS with β Decays. From the results for SUVs and TNRs, shown in Figs 1 
and 2, following the procedure described previously in the text, we obtained the counting rates expected in a real 
application scenario. The results are shown in Fig. 4, where in addition to the usual division between local lesions 
Figure 3. ROC curve for lymph node lesion number 1 (top), and distribution of Area Under Curve of ROCs of 
all the considered patient (bottom). The AUC for the shown case is 0.9951. The blue (continue) line represents 
lymph nodes, while the red (dotted) line represents local lesions. The probing time has been fixed to =t 3sprobe .
Figure 4. Counting rates expected on lesions (Signal) versus the ones expected on healthy tissue. The dashed 
line shows the bisector, representing the case in which the probe gives the exact same count over signal than 
over healthy tissue, having thus no sensitivity at all. In addition to the usual division among local lesions and 
lymph nodes, points are also classified (“Good” or “Bad”) according to the ROC sensitivity test described in the 
text, having fixed a probing time of 3 s and requiring > .AUC 0 95. The rates correspond to the application case 
described in the text (injection of 210 MBq of 68Ga-PSMA 150min before the surgery).
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and lymph nodes the classification based on ROC sensitivity test is also shown (“Good” if > .AUC 0 95, “Bad” 
otherwise). Here the bisector represents the “worst case”, in which lesion and healthy tissue give the same rate. 
Median probing time (tprobe) was .3 0s (IQR 1.5–5.5 s).
In Fig. 5 the detecting times needed for the probe to discriminate the tumor from the surrounding healthy 
tissue, as described earlier in the text, are shown in an histogram, while in Fig. 6 the correlation between the 
ROC-AUC and the minimum time is reported.
Discussion
SUVs are found as foreseen to differ significantly between the lesions, ranging from less than 2 in the lowest cases 
up to about 20. No particular difference appears to be present if the lesion is local or a lymph node, since the two 
populations seem to show analogous mean uptake.
A similar behaviour is exhibited by TNRs, that range from a minimum value of about 1.5 to a maximum value 
of above 60, with only a slight, non relevant, preference of lymph-nodes for higher values.
The vast majority of cases seem to show good TNR, of the same order of magnitude of those found for 
DOTATOC in case of meningioma, glioma5 and Neuro Endocrine Tumors (NET)6. However, while in those cases 
the efficacy of the technique is boosted by the pure β− emission of 90Y-DOTATOC, with substantially no γ con-
tamination, in case of 68Ga-PSMA the presence of the abundant photon flux due to positron annihilation leads to 
a remarkable worsening in the quality of the ratio between counting rate on the tumor and on healthy tissue. It is 
to be noted that 90Y-PSMA would be the optimal tracer, but its use in clinics is still not established18.
Figure 5 suggests that a probing time ∼t 5probe  is enough for the great majority of lesions to be identified 
accurately. These times, despite being considerably longer than those in case of pure β−-RGS6, seem however to 
Figure 5. Distribution of tprobe needed to be able to discriminate with sufficient accuracy the tumor. The 
statistical criterion used and the real case scenario considered are detailed in the text. The blue (continue) line 
represents lymph nodes, while the red (dotted) line represents local lesions.
Figure 6. Area Under Curv of ROCs as a function of the minimum tprobe calculated for each of the 58 lesions. In 
addition to the usual division among local lesions and lymph nodes, points are also classified (“Good” or “Bad”) 
according to the ROC sensitivity test described in the text, having fixed a probing time of 3 s and requiring 
> .AUC 0 95.
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be compatible with an application scenario, especially considering that there is a “reaction time” of the surgeon 
that is estimated to be of the order of few seconds, independently from the probe signal.
The ROC sensitivity test described above suggests that the technique has very good discriminating power for 
the vast majority of cases, since from Fig. 3 (bottom) it stems that almost all the considered lesions have an AUC 
of more than 80% with a reasonable =t 3sprobe . Setting a conservative cut at ≥AUC 95% identifies “badly dis-
criminated” cases, which represent lesions characterised by very low TNR, that are those in which the applicabil-
ity of this technique is expected in fact to be more difficult and therefore cluster close to the bisector in Fig. 4. 
These cases correspond to values of tprobe exceeding severals tens of seconds (see Fig. 5), for which this technique 
to be applicable would require a greater activity to be administered to the patient, with all the associated conse-
quences in terms of radio-protection issues, both for the patient and for the medical personnel.
However it is crucial to highlight that the application protocol of β-RGS foresees a preliminary PET image 
with 68Ga-PSMA precisely to demonstrate that the lesion of interest shows a TNR good enough to make the 
patient a possible candidate for such a technique.
As far as radio protection issues are concerned, same considerations standing for proposed β+-RGS tech-
niques19 hold also in this case. Moreover, it has to be stressed that 68Ga has an mean lifetime that is approximately 
half of the one of 18F. This means that the use of the former would imply a much reduced radiation load both to 
the patient and to the medical staff.
It is finally to be noted that the current estimate is made with a detector optimised for 90Y and that improve-
ments can be foreseen by either increasing the electron efficiency or decreasing the sensitivity to photons, for 
instance with the use a solide state β detector.
Conclusions
The goal of this study was to evaluate the possibility to use the β probe we have developed for β-RGS with a high 
energy β+ emitting radio pharmaceutical, exploiting the high sensitivity of the detector, in order to extend the 
application cases of such a technique.
To this aim, we evaluated the uptake of 68Ga-PSMA in prostatic cancer recurrences in a retrospective study on 
PET images of 45 patients at Policlinico Sant’ Orsola Malpighi in Bologna.
Despite the expected variability among patients, both in terms of SUV (median 4.1, IQR 3.0–6.1) and TNR 
(median 9.4, IQR 5.2–14.6), the majority of cases have been found to be compatible with the application of the 
proposed technique in a reasonable scenario of injected activity and probing time. There are however some cases 
in which the technique to be effective would require either a grater amount of administered activity or a longer 
probing time.
The main result of this study is that most cases of prostatic cancers showing uptake for 68Ga-PSMA are good 
candidates for β-RGS. The preliminary PET image with 68Ga-PSMA, foreseen in the application protocol, would 
however allow to know in advance if the considered patient is a good candidate or not, also allowing to tailor the 
amount of activity to inject to the particular uptake.
To this aim, ex-vivo tests on excised tumor specimens are needed and foreseen for the next future, in order to 
assess the precise criteria to discriminate patients eligible for this RGS technique.
On the other hand, studies are being carried out to investigate possible novel detecting techniques to be used 
in the probe, for example focusing on solid state sensors (CMOS). This development of the instrument could 
allow to lower significantly the energy threshold for detecting electrons, thus improving the efficacy in an appli-
cation case like the one discussed in this study.
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